{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:45Z","timestamp":1790788725143,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008635","name":"University of Texas Health Science Center at San Antonio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clml.2019.05.012","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T04:31:34Z","timestamp":1559017894000},"page":"665-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Geraldine","family":"Faivre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew James","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.05.012_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/asheducation-2006.1.311","article-title":"An update on therapy of primary central nervous system lymphoma","author":"Deangelis","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2019.05.012_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-007-9397-0","article-title":"Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly","volume":"85","author":"Omuro","year":"2007","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.clml.2019.05.012_bib3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/WCO.0000000000000145","article-title":"Challenges in the treatment of elderly patients with primary central nervous system lymphoma","volume":"27","author":"Roth","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clml.2019.05.012_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23551","article-title":"The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin lymphoma","volume":"88","author":"O\u2019Neill","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.05.012_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.14522","article-title":"Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma","volume":"177","author":"Karmali","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.05.012_bib6","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.05.012_bib7","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/leu.2017.170","article-title":"High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group","volume":"31","author":"Kasenda","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.012_bib8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.05.012_bib9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2017.23","article-title":"High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study","volume":"52","author":"Schorb","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.05.012_bib10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.05.012_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-017-2435-7","article-title":"Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study","volume":"133","author":"Houillier","year":"2017","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.clml.2019.05.012_bib12","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide vs. methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.05.012_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","article-title":"Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group","volume":"100","author":"Pulczynski","year":"2015","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:17Z","timestamp":1761870797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019301752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2152265019301752"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}